MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) — Veru Inc. VERU, a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical…Read More
Veru Announces Appointment of Dr Erik Swenson and Dr Robert Schooley to its Infectious Disease Scientific Advisory Board Veru NASDAQVERU
